Abstract: |
Peripheral T-cell lymphomas (PTCL) include a group of heterogeneous and rare lymphomas. The T-cell phenotype is an independent poor prognostic feature and these lymphomas have a lower cure rate with chemotherapy than with their B-cell counterparts. Retrospective studies suggest that high-dose therapy and autologous stem cell transplant (HDT-ASCT) may be feasible and effective for some patients in the salvage setting. However, many of these studies are biased by the inclusion of patients with ALK + anaplastic large cell lymphoma, an entity known to have a relatively positive prognosis with chemotherapy. Because PTCL have a generally poor prognosis, HDT-ASCT has been studied in first complete or partial remission for these patients as consolidation with favorable outcomes noted. However, there are currently no randomized trials that establish upfront HDT-ASCT as standard of care for patients with PTCL. Allogeneic transplantation is becoming more frequently used for these patients, as there is growing evidence for a graft-versus-lymphoma effect in these diseases and a growing acceptance for reduced intensity conditioning regimens. But, there continues to be limited data describing allogeneic transplantation for these diseases and, thus, the application of this modality of therapy for PTCL is still unclear. © 2013 Springer Science+Business Media New York. All rights reserved. |